Previous studies have shown significant success in targeting HCC cells using a humanized anti-GPC3 monoclonal antibody (GC33), and results indicated significant inhibition of GPC3-positive human HCC xenograft tumor growth in SCID mice while the GPC3-negative HCC xenografts were unaffected, proving the potential role of targeting HCC tumor cells through this ligand [216,220]. The gene discussed is GPC3; the disease is neoplasm.